NCT03775070: SavDCM

Simvastatin Therapy in Patients With Dilated Cardiomyopathy.

Completed Phase 2 Last updated 3 August 2022

What this trial tests

Phase 2 trial testing Simvastatin in Dilated Cardiomyopathy in 8 participants. Completed in 31 July 2022.

Timeline

17 January 2019

Primary endpoint
31 July 2022

31 July 2022

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	17 January 2019
Primary completion	31 July 2022
Estimated completion	31 July 2022
Sites	1 location across Taiwan

Drugs / interventions tested

• Simvastatin (simvastatin) — full drug profile →

Conditions studied

• Dilated Cardiomyopathy — all drugs for Dilated Cardiomyopathy →

Sponsor

National Taiwan University Hospital

Who can join

Eligibility, any sex, with Dilated Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated with significant early morbidity and mortality. About half of patients die or require heart transplantation within 5 years of diagnosis. The medical therapy for DCM with heart failure includes anti-congestive medications and antiplatelet therapy. Those who fail to improve within the first year of diagnosis usually deteriorated even upon aggressive anti-congestive medications. The investigators had conducted precision-medicine-based approach to provide strategic approach as drug repurposing to identify new treatments. The investigators have identified the beneficial effects from a statin, simvastatin, to restore the cardiac contractility. The investigators would further assess the efficacy of simvastatin to improve the cardiac function in patients with DCM.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. An up-to-date overview of computational polypharmacology in modern drug discovery.
   Chaudhari R, Fong LW, Tan Z, Huang B, et al · · 2020 · cited 46× · PMID 32452701 · DOI 10.1080/17460441.2020.1767063
2. Single-Cell RNA Sequencing Reveals Cardiac Fibroblast-Specific Transcriptomic Changes in Dilated Cardiomyopathy.
   Russell-Hallinan A, Cappa O, Kerrigan L, Tonry C, et al · · 2024 · cited 11× · PMID 38727290 · DOI 10.3390/cells13090752